While seeking to activate upstream proteins such as p53 may seem to be a suitable strategy for induction of senolysis compared to targeting individual downstream proteins such as Bcl-2 or Bcl-xL, it also carries significant risk of unwanted effects if used as a target in neurodegenerative disorders, including ALS. This evidence concerns the gene BCL2L1 and amyotrophic lateral sclerosis.